Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205404 | 1.00 | HTR6 (1.00) | HTR6 | |
| SCHEMBL315319 | 0.85 | HTR6 (1.00) | HTR6 | |
| SCHEMBL315318 | 0.85 | HTR6 (1.00) | HTR6 | |
| SCHEMBL315990 | 0.85 | HTR6 (1.00) | HTR6 | |
| SCHEMBL315991 | 0.85 | HTR6 (1.00) | HTR6 | |
| SCHEMBL317065 | 0.84 | HTR6 (1.00) | HTR6 | |
| SCHEMBL316130 | 0.84 | HTR6 (0.75) | HTR6 | |
| SCHEMBL317064 | 0.84 | HTR6 (1.00) | HTR6 | |
| SCHEMBL19296356 | 0.83 | HTR6 (0.72) | HTR6 | |
| SCHEMBL315347 | 0.82 | HTR6 (1.00) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671235-B2 | N-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-N-methyl-methanesulfonamide; 5-HT6 and 5-HT2A receptor modulators; selectiveserotonin reuptake inhibitors; selective seotonin receptor antagonists;gastrointestinal disorders; irritable bowel syndrome; cental nervous system | ROCHE PALO ALTO LLC (US) | 2010-03-02 | — | — | US | claimed |
| EP-2035370-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-03-18 | — | — | EP | claimed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | claimed |
| WO-2007147771-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | claimed |
| US-7981923-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100130742-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HARRIS III RALPH NEW | 2010-05-27 | — | — | US | disclosed |
| US-7671235-B2 | N-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-N-methyl-methanesulfonamide; 5-HT6 and 5-HT2A receptor modulators; selectiveserotonin reuptake inhibitors; selective seotonin receptor antagonists;gastrointestinal disorders; irritable bowel syndrome; cental nervous system | ROCHE PALO ALTO LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2035370-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147771-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | INSRR, TTN, INSR | HTR6 1360/4885 |
| US-20100130742-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, TTN, INSR | HTR6 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.